Juillière Y
Cardiologie B CHU Nancy-Brabois, Vandoeuvre-lès-Nancy.
Rev Prat. 1997 Dec 1;47(19):2125-9.
Angiotensin-converting-enzyme inhibitors increase life expectancy in congestive heart failure, and they have thus changed the therapeutic strategy. The well tolerated highest daily dosage has to be used. Diuretics are often associated with vasodilators; however, they have to be administered at a minimal chronic daily dosage, in order to avoid deleterious neurohormonal effects. Digoxin keeps a great interest, as the unique positive inotropic agent without surmortality. Nitrates associated or not with hydralazine may show an additional interesting benefit. The role of other vasodilators, namely amlodipine and losartan, in the treatment of chronic heart failure remains to be defined. New vasodilators are in development and might further increase our therapeutic possibilities against congestive heart failure.
血管紧张素转换酶抑制剂可提高充血性心力衰竭患者的预期寿命,因此改变了治疗策略。必须使用耐受性良好的最高日剂量。利尿剂常与血管扩张剂联合使用;然而,为避免有害的神经激素作用,必须以最低的慢性日剂量给药。地高辛作为唯一一种不增加死亡率的正性肌力药物,备受关注。硝酸盐与肼屈嗪联合或不联合使用可能会显示出额外的有益效果。其他血管扩张剂,即氨氯地平和氯沙坦,在慢性心力衰竭治疗中的作用仍有待确定。新型血管扩张剂正在研发中,可能会进一步增加我们治疗充血性心力衰竭的可能性。